INSTITUTO-COORDENADAS
23.6.2020 18:13:05 CEST | Business Wire | Press release
In the socioeconomic recovery of Europe’s main cities following the effects of the Covid-19 pandemic, a commitment to healthcare, innovation and medical research is a key element. In that regard, Barcelona and the surrounding area play a European leadership role, uniting a powerful healthcare field with a high quality scientific research network. And according to the initial conclusions of a study by Instituto Coordenadas, the city’s response to Covid-19 is an example of public-private partnership.
The response of the healthcare sector, ensuring Barcelona is a safe city, combines with the Catalan capital’s research efforts over several decades and its strength in recruiting talent for innovation and research in biotechnology and health. The city’s hospital network, for instance, has made great strides in both medicine and research during the crisis. Some of the main achievements in that regard include the work of Hospital Clínic, and its partnership with the US-based MIT research team in particular, and the Vall d’Hebron University Hospital, which has been congratulated by the World Health Organization (WHO) for managing the fight against the pandemic. Another example of Barcelona’s dominant position lies in the work of the SciTech DiploHub, an initiative that has succeeded in bringing together the field of international scientific diplomacy.
Barcelona’s public-private scientific ecosystem has also been at work during the Covid-19 threat, with around 20 initiatives placing Catalonia’s capital at the forefront in the fight against the pandemic. Examples go from top level clinical trials, such as the one carried out by Germans Trias i Pujol Research Institute (IGTP) to stop those with the virus spreading it further, to IQS’s efforts to find an inhibitor for attacking one of the receptors of Covid-19. Most recently, the expertise of three doctors from Barcelona’s ISGlobal played a key role in redressing the errors relating to the effectiveness of hydroxychloroquine as regards Covid-19, and there is also the example of the work being carried out into new treatments for eliminating cytokine storms.
Another development that has put Barcelona on the front line has been the global partnership between the city’s six cutting-edge science centres, 110 pharmaceutical companies – with their long-standing relationship with the city – and biotech businesses and start-ups based at the Barcelona Science Park (PCB). The aim of the alliance is to secure an effective antiretroviral drug for fighting Covid-19, vaccines and more effective rapid diagnostic tests.
PCB, with its 2,800 professionals, was Spain’s first science park and is home to IRB Barcelona, which is one of the research centres selected by the European Union to identify an effective vaccine, new treatments and better rapid diagnostic tests. In fact, of the 17 projects selected in Europe, five come from Barcelona and the surrounding area.
The fight against the virus has seen the whole of the local research network entering into partnership. For instance, the Barcelona Supercomputing Center (BSC) has made its Mare Nostrum supercomputer available to researchers so they can fight the pandemic using artificial intelligence and bioinformatics.
In short, this array of alliances has put Barcelona in a position of excellence on the European map of efforts to fight Covid-19.
ABOUT INSTITUTO COORDENADAS DE GOBERNANZA Y ECONOMIA APLICADA
The institute develops thought and undertakes research into the interaction between governance and applied economics in order to make constructive and decisive progress in three fundamental issues: social wellbeing, economic progress and environmental sustainability. This takes place in a context of development and evolution, unprecedented since the end of the 18th century and the beginning of the 19th century with the industrial revolution. Faithful to its founding principles of independence, non-partisanship and plurality, the institute is a proactive leader of the fusion between the essence and innovation of economic liberalisation as the best model for tackling the challenge of the present and the future in Spain, Europe and the world.
Further information: www.institutocoordenadas.com
NOTE: The information contained in this press release is a public interest summary from reports and studies based on analysis and research; expert working groups and sessions; and/or production of scientific articles by Instituto Coordenadas de Gobernanza y Economía Aplicada. The original and complete documents are for internal use and are the sole property of Instituto Coordenadas de Gobernanza y Economía Aplicada.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005751/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Datato Boehringer Ingelheim2.9.2026 14:00:00 CEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 14:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha® Portfolio2.9.2026 13:37:00 CEST | Press release
Healthcare professionals in eligible markets can now access the Instructions for Use for the saypha® portfolio digitally by scanning a QR code on the product packaging Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructio
Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building2.9.2026 13:13:00 CEST | Press release
Orascom and Muriya press ahead across Hawana Salalah, Jebel Sifah and the US$90M+ As Sodah Island, signalling long-term conviction in Oman’s future, in step with Vision 2040. Across Oman, Orascom Development and its Sultanate platform, Muriya, are moving forward. While parts of the region grow cautious, Muriya has paused nothing, building and delivering across all three destinations: Hawana Salalah, Jebel Sifah and As Sodah Island. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260902781576/en/ Moving Forward in Oman: Orascom, Samih Sawiris and Muriya Keep Building (Photo: AETOSWire) The same steadiness runs through everything Samih Sawiris and Orascom have built, from El Gouna to Andermatt to Mamula Island: identifying extraordinary places and developing them for the long term. “Oman has everything we look for as a long-term developer: stability, natural beauty, and a clear direction for its future. Our continued investment
Aukera Closes €460 Million Structured Credit Facility Led by EIG to Support European Energy Infrastructure Portfolio2.9.2026 13:00:00 CEST | Press release
Aukera, the pan-European battery storage and renewable energy platform backed by AtlasInvest, Reggeborgh and SFPIM (Belgium's sovereign wealth fund), announced the closing of its €460 million structured credit facility, for which EIG, a leading institutional investor in the global energy and infrastructure sectors, served as the lead investor. With the financing in place, Aukera moves into its next phase of growth, combining capital, expertise and delivery capability to build a significant European energy infrastructure platform that develops, finances, constructs and operates assets at scale. The original facility included an initial €200 million commitment and an accordion feature of up to €250 million. The amended facility converts that accordion into a firmly committed €260 million Series 2 tranche, increasing total committed capital to €460 million. The additional capital will support the continued advancement of Aukera's portfolio of renewable energy generation, battery storage a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
